Drug Profile
BTH 1704
Alternative Names: AS-1402; BTH-1704; HuHMFG1; Monoclonal antibody HMFG1; R-1550; TherexLatest Information Update: 15 Jan 2021
Price :
$50
*
At a glance
- Originator Cancer Research UK
- Developer Antisoma; Biothera; University of Illinois at Chicago
- Class Antineoplastics; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Immunostimulants; Mucin 1 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Pancreatic cancer
- Discontinued Breast cancer
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for phase-I development in Pancreatic-cancer(Combination therapy, Late-stage disease, Second-line therapy or greater) in USA (IV)
- 01 May 2014 Phase-I clinical trials in Pancreatic cancer (combination therapy, late-stage disease, second line therapy or greater) in USA (IV)
- 11 Mar 2011 Biothera acquires rights for AS 1402 from Antisoma